RNA Outsourcing Resources

  1. Advanced Therapies Going Mainstream: Are We There Yet? 11/14/2025

    Advanced therapies are nearing mainstream adoption, with cell, mRNA, and oligonucleotide treatments expanding into broader indications. Learn what’s driving this shift and what manufacturers must do.

  2. Enhancing Safety And Efficacy Of mRNA-Based Therapeutics 2/11/2025

    Discover how Codex® HiCap RNA Polymerase optimizes mRNA yield while reducing dsRNA byproducts for safer, more effective therapeutics.

  3. Optimizing qPCR For Broad-Range Transcript Detection In Anti-PD-1 Therapy 4/23/2025

    Optimize qPCR protocols for greater sensitivity and reproducibility to accurately measure immune-related gene expression and better identify patients who will benefit from anti-PD-1 immunotherapy.

  4. How Smaller Biotechs Are Rethinking CRO Relationships Post-Pandemic 3/9/2026

    Smaller biotechs are rethinking CRO partnerships, valuing speed, scientific access, flexibility, and transparent pricing over scale — driven by pandemic lessons and a sharper focus on operational fit.

  5. mRNA Therapeutic Development Through Enhanced IVT Capping Efficiency 4/16/2025

    See how Codex HiCap RNA Polymerase supports the production of high-performance synthetic mRNA, paving the way for next-generation mRNA therapies.

  6. Analytical Method Release And Stability Platform For RNA Drug Substance 3/14/2025

    We offer comprehensive analytical support across the R&D space, including method development, validation, process characterization, in-process testing, process validation, and GMP release testing.

  7. Phase IIb Trial: Evaluating A Novel Treatment For Locally Advanced Or Metastatic Breast Cancer 12/5/2024

    This case study highlights a successful Phase IIb clinical trial conducted by an Indian biotech company evaluating a novel treatment for Locally Advanced or Metastatic Breast Cancer.

  8. Reducing Costs & Risks: A Pharma Guide To FTZ Subzones For U.S. Drug Manufacturing 2/11/2025

    Utilized wisely, FTZs and subzones can be tools for cost savings and can enable pharma companies to leverage the benefits of American manufacturing.

  9. A New Centre For Continuous mRNA Manufacturing 5/14/2024

    Explore how a partnership between academia, regulatory agencies, and manufacturing organizations has the potential to reshape the way we produce and distribute mRNA-based therapies.

  10. High-Throughput Platform Propels Gene Editing Therapy Research 3/1/2024

    Explore the potential of polymeric nanoparticles (PNPs) as an alternative to viral vectors. PNPs offer design flexibility, enabling larger payloads, targeted release, and minimized side effects.